Monographie - Tobramycin sulfate

Pēdējā atjaunošana :
19/11/2024

Tobramycin sulfate

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Bactob	Indija
Beltob	Indija
Bramicil	Itālija
Brulamycin	Ungārija, Vācija
Eltol	Indija
Fytobra	Indija
Gernebcin	Vācija
Komitob	Indija
Nebcin	Austrālija, Dienvidāfrikas Republika, Ēģipte, Grieķija, Jaunzēlande, Lielbritānija, Saūda Arābija
Nebcina	Dānija, Maroka, Norvēģija, Zviedrija
Nebcine	Francija, Maroka
Nebicina	Itālija
Obracin	Beļģija, Holande, Luksemburga, Šveice
Tobel	Turcija
Tobra	Vācija
Tobra-Gobens	Spānija
Tobraalex	Ēģipte
Tobracin	Ēģipte
Tobradistin	Spānija
Tobramicina	Itālija, Portugāle, Spānija
Tobramina	Brazīlija
Tobramycin	Amerikas Savienotās Valstis, Austrālija, Īrija, Kanāda, Lielbritānija, Norvēģija, Vācija
Tobramycine	Beļģija, Holande, Luksemburga
Tobrasix	Austrija
Tobrazid	Vācija
Tomycin	Somija

Literatūras saraksts : Tobramycin sulfate

	tips	publicēšana
3	Žurnāls	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
13	Žurnāls	Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
19	Žurnāls	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Žurnāls	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Žurnāls	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Žurnāls	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Žurnāls	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Žurnāls	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Žurnāls	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
129	Žurnāls	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	Žurnāls	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Žurnāls	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Žurnāls	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Žurnāls	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Žurnāls	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Žurnāls	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
285	Žurnāls	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Žurnāls	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Žurnāls	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Žurnāls	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Žurnāls	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
335	Žurnāls	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Žurnāls	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Žurnāls	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
367	Žurnāls	Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119.
384	Žurnāls	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Žurnāls	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Žurnāls	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Žurnāls	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Žurnāls	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
434	Žurnāls	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
472	Žurnāls	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	Žurnāls	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Žurnāls	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
494	Žurnāls	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Hosp Pharm 1992 ; 49: 836,838.
496	Žurnāls	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	Žurnāls	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
503	Žurnāls	Nahata MC, Durrell DE. Stability of tobramycin sulfate in admixtures with calcium gluconate. Am J Hosp Pharm 1985 ; 45: 1987-1988.
565	Žurnāls	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.
575	Žurnāls	Holmes CJ, Ausman RK, Kundsin RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
604	Laboratorija	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
612	Žurnāls	Frable RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627.
639	Žurnāls	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
660	Žurnāls	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
673	Žurnāls	Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN 1989 ; 13: 505-509.
709	Žurnāls	Seitz DJ, Archambault JR, Brinck-Johnsen T. Stability of tobramycin sulfate in plastic syringes. Am J Hosp Pharm 1980 ; 37: 1614-1615.
889	Žurnāls	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905	Žurnāls	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Žurnāls	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Žurnāls	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Žurnāls	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Žurnāls	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1168	Žurnāls	Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H. Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin. Antimicrob Agents Chemother 1983 ; 23: 653-657.
1206	Žurnāls	Frear RS. Cefoperazone-aminoglycoside incompatibility. Am J Hosp Pharm 1983 ; 40: 564.
1232	Žurnāls	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Žurnāls	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Žurnāls	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Žurnāls	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Žurnāls	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1611	Žurnāls	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Žurnāls	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1704	Žurnāls	Xu QA, Trissel LA, Saenz A. Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags. Int J Pharm Compound 2002 ; 6: 152-154.
1712	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Žurnāls	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1745	Žurnāls	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Health-Syst Pharm 1992 ; 49: 836-838.
1754	Žurnāls	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	Žurnāls	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800	Žurnāls	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Žurnāls	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Žurnāls	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Žurnāls	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Žurnāls	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	Žurnāls	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Žurnāls	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Žurnāls	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Žurnāls	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Žurnāls	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Žurnāls	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Žurnāls	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Žurnāls	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	Laboratorija	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2353	Žurnāls	Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate. Int J Pharm Compound 2000 ; 4, 6: 476-479.
2369	Žurnāls	Mason NA, Johnson CE, O'Brien MA. Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 1139 - 1142.
3012	Žurnāls	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3122	Žurnāls	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3152	Žurnāls	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3201	Žurnāls	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	Žurnāls	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Žurnāls	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Žurnāls	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorija	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Žurnāls	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Žurnāls	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3522	Laboratorija	Flucloxacillin - Summary of Product Characteristics. Actavis 2013
3523	Laboratorija	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	Laboratorija	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3527	Laboratorija	Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018
3540	Laboratorija	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3543	Laboratorija	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3544	Laboratorija	Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006
3545	Laboratorija	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3546	Laboratorija	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	Laboratorija	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3578	Laboratorija	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3586	Laboratorija	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Laboratorija	Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3594	Laboratorija	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3644	Laboratorija	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3656	Laboratorija	Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014
3674	Laboratorija	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3677	Laboratorija	Cefpirome (Cefrom®) - Résumé des caractéristiques du produit Sanofi Aventis France 2008
3687	Laboratorija	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Žurnāls	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767	Žurnāls	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Žurnāls	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	plakāts	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakāts	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakāts	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	Laboratorija	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Žurnāls	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Žurnāls	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4319	Žurnāls	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Žurnāls	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Žurnāls	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4445	Žurnāls	Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D. Antibiotic compatibility and stability in a parenteral nutrition solution. Chemotherapy 1979 ; 25: 336-345.
4528	Žurnāls	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Žurnāls	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratorija	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Žurnāls	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Žurnāls	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales